Company: IOBT
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047744
Chunk: 31

Company: IO Biotech, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 31
---
 improved to 50% for the latest included patients with a minimum follow-up of 30 months. We believe these data indicate good quality responses with a deep and durable response in most of the patients (Figure 9). 

The median DOR was 27 months as of the January 5, 2023 cut-off date in the MM1636 trial, and 20 of the 22 patients with a radiologically confirmed response (at 12 weeks after the first response) had a response lasting greater than 182 days providing a durable response rate of 66.7% (20/30) (Figures 9 and 10).

26

Figure 9: MM1636 Cohort A—Durability and Deepening Responses 

CR = complete response, PR = partial response, PD = progressive disease 

Figure 10: MM1636 Cohort A—Duration of Response 

Tumor Shrinkage and Durability of Response in Individual Patients Over Time in Cohort A 

The rapid onset of response, deepening of responses over time and durability of responses in the MM1636 trial are shown in the spider plot for individual patients. Green, blue and red lines respectively indicate CR, PR and PD. Only six out of 30 patients experienced progressive disease at the first imaging timepoint (12 weeks) marked with red lines (Figure 11). 

27

Figure 11: MM1636 Cohort A—Change in Target Lesions from Baseline Over Time 

PFS in Patients from Cohort A

At a median duration of follow-up of 45.3 months (Figure 12), the median PFS was 25.5 months. 

Figure 11: MM1636 Cohort A—Progression Free Survival 

+ Censored; dotted lines show 95% Confidence Limits 

Overall Survival  

28

At a median duration of follow-up of 45.3 months, the median OS had still not yet been reached (Figure 12). 

Figure 13: MM1636 Cohort A—Overall Survival 

+ Censored; dotted lines show 95% Confidence Limits 

Phase 1/2 Correlative Data 

Correlative biomarker data from the MM1636 trial support the mechanism of action of Cylembio® in treated patients, based on the following observations: 

•Induction of systemic therapy (IO102+IO103)-specific T cell response in blood was confirmed in over 96% of treated patients (Table 4); 

•Confirmation of Cyle